The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of key presentations and posters of interest.
In this episode From the Vault, Roger Green interviews physician, author, and entrepreneur Marcus Ranney about his experiences, the ability of data and digital health to empower health seekers. They also visit the foundational vision that led him to form Human Edge and develop the Mito app.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver disease. This conversation explores the use of FIB-4 as a front-line tool for primary care. The advocates share their final thoughts on a change they can make in their country in the next 12 months that might extend beyond the country’s borders.
The panelists investigate the economics of pathway design within a wider discussion on the role of patient empowerment in putting a dent in Fatty Liver disease. This conversation observes challenges and opportunities for effective solutions.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation highlights patient advocate contributions toward developing clinical care pathways and guidelines.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores the prospect of digital therapeutics as a Pharma-supported patient wellness tool.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores patient needs and inputs for trial design and the extent to which they are considered.
Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. The group explores topics ranging from the economics of drug development to the future of digital therapeutics, all centering around the patient perspective.
Does the NICE Draft Guidance and methodology reveal a bad fit between the NICE mode of analysis and wellness-oriented solutions like early NAFLD screening?
Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to discuss the recent NICE meeting on use of VCTE in primary care settings. In this conversation, the group explores how to create and train on delivering meaningful test results to patients.
Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to investigate the link between socioeconomic status and liver health outcomes. In this episode, the group discusses the challenges of developing accessible pathways and who will administer FibroScan in a community setting.
Roger Green, Louise Campbell, Professor Ian Rowe and Dr Kathryn Jack discuss a process used in the UK called “commissioning through evaluation.” Mid-conversation, Professor William Alazawi joins an investigation into political pressures and metaphorical issues that shape the differences between cancer and liver disease management.
Roger Green and Louise Campbell are joined by Professor Ian Rowe and Dr Kathryn Jack to discuss the recent NICE meeting on use of VCTE in primary care settings. The group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice in community settings.
Roger Green and Louise Campbell are joined by Professors Ian Rowe and William Alazawi and Dr Kathryn Jack to discuss the recent NICE meeting on use of FibroScan in primary care settings. As part of the discussion, the group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice.
This episode From the Vault uses quotes from Surfing the NASH Tsunami’s NASH-TAG 2022 coverage and comments from Roger Green to explore what we learned about combination therapies.
Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation the group discusses Phase 3 results of the REVERSE trial by Intercept.
Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation Stephen presents interim data from Axcella’s Phase 2B EMMPACT Study.
Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the group explores more positive Phase 2B results from Poxel’s DESTINY-1 Trial.
Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss eye-opening Phase 2B results from Akero’s HARMONY Trial.
Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss the positive results of Altimmune’s 12 week Phase 1B study of pemvidutide.
Stephen Harrison and Mazen Noureddin join regulars Jörn Schattenberg, Louise Campbell and Roger Green to review five recent press releases reporting on trial results from Altimmune, Akero, Poxel, Axcella and Intercept. Dubbed a Wow! episode, the panelists explore some of the most exciting and promising data of the last decade in NASH drug development.
Professor Ian Rowe joins Surfers Louise Campbell and Roger Green to discuss the important Fatty Liver stories of summer 2021. He focuses on the recent FDA approval of the ELF test for prognosis of cirrhosis.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they discuss the importance of combination NIT biomarkers in developing a viable system for treating patients.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they identify the potential bottlenecks in getting drugs to NAFLD patients.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they discuss the implications of positive drug trials and eventual approvals on NAFLD treatment.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they address the role of multiple biomarker tests in the diagnostic process.
Surfers Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they explore the increasing demand for collaboration between medical specialties as opinion leaders come to see NAFLD as part of a constellation of metabolic diseases.
Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.
In a review of the 2022 NAFLD Summit, program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green to discuss the impact of weight change and lifestyle modification in clinical trials while utilizing insights from the bariatric and diabetes fields. This episode From the Vault comes from Season 2, Episode 61.3 where Roger Green, Stephen Harrison, Ali Aminian and Wayne Eskridge discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses the impact of weight change and lifestyle modification in clinical trials.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group explores issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group contextualizes and compares the NAFLD Summit to other major liver conferences and meetings. The group also assesses Session 9 from Friday, a series of case studies on why trials fail.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses underreported alcohol use in clinical trials and the impact of treating comorbidities on the treatment of NAFLD.
The 2022 NAFLD Summit proved to be an in-depth, successful conference brought to life by key opinion leaders in fatty liver and metabolic disease from around the world. In Season 3, Episode 46, Surfer Roger Green hosts a review on site in Dublin with presenting speakers Mazen Noureddin, Sven Francque and Hannes Hagström.
In this conversation From Inside the Vault, NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin and retrospective analysis co-leads Naim Alkhouri and Jörn Schattenberg join Louise Campbell and Roger Green to discuss designs and plans for NAIL-NIT retrospective analysis.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this final conversation, the group explores the rest of the Day Two program, focusing on the development of an NIT diagnostic pathway. Finally, each offers their closing remarks on being a part of the 8th Paris NASH Meeting and what the future looks like in this space.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses the opening and closing sessions, data collection and the rate of growth for cirrhosis, and Fatty Liver in the metabolic context.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group shares one particularly striking takeaway from the meeting.
The importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meeting. Last week, Surfers Roger Green, Louise Campbell and Jörn Schattenberg were in attendance alongside patient advocate and episode guest, Jeff McIntyre.
In this episode From the Vault, Jörn Schattenberg, Stephen Harrison and Roger Green review some highlights from the 2021 Paris NASH Meeting. This conversation looks at the Day Two sessions and the overall implications of the meeting.
In Part 2 of Season 3, Episode 44, host Roger Green kicks off a series of 1 on 1 interviews with friend of the podcast, Dr. Jeffrey Lazarus. In this conversation, the two discuss a preview of NAFLD Summit 2022 in Dublin, 15-17 September.
In Part 2 of this episode, host Roger Green interviews podcast friend and frequent guest, Dr. Jeffrey Lazarus. In this conversation, they discuss the NAFLD Nomenclature Conference held in July.
In this conversation, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to talk about Paris NASH 2022. The group explores their hopes in terms of immediate and long term outcomes of the meeting.
In a preview of the 2022 Paris NASH Meeting, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss the opening session. The group explores potential insights that will contextualize NASH in the scope of an integrated multi-specialty approach.
In a preview of the 2022 Paris NASH Meeting, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss what each looks forward to most in the upcoming panels and discussions. “Brave one go first.”
In a preview of Paris NASH and the NAFLD Summit 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss what each looks forward to in the upcoming meeting. Additionally in a part 2 of this episode, Prof. Jeff Lazarus from the Barcelona Institute for Global Health joins Roger for a one on one interview. Jeff shares a snapshot into what he has been working on over the past few months, as well as his anticipated interests on the NAFLD Summit agenda.
Earlier this year, the “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) got back together with no other guests to talk about the role that combination NASH drugs and greater population diversity in clinical trials will play to strengthen NASH drug development.
First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the future of combination agents in NASH Therapy.
First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the optimization of combination agents in NASH Therapy. The conversation takes a broader look into the strategies behind developing and pairing combination agents and the role they can potentially play in a wider scope of treatment.
First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the panel continues its discussion around strategies for deciding which agents to combine in trials, along with a plea for larger BioPharma companies to pursue science partnerships with smaller companies even if there are no strong commercial bonds between the companies. In the end, discussion of the ongoing LEGEND trial gives panelists a chance to express different opinions about combination agent strategy.
n Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the group explores the role of NITs as the prime diagnostic tool alongside combination agents, and discusses practical issues surrounding patient management and theoretical ones in deciding which agents to combine for trials.
In Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The theme of the episode is to explore the role of combination agents for NASH therapy over time. This opening conversation focuses on the design and execution of the triple-agent study, and how it may contribute to fibrotic regression.
Naim Alkhouri and Mazen Noureddin join the Surfers to discuss the future role of Combination Agents with NASH therapy, stemming from their recently published article, Safety and efficacy of combination therapy with semaglutide,cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The conversation focuses more broadly on the benefits and future of combination therapies for NASH patients.
From February this year, this conversation lead by Louise Campbell explores the need for and value of patient education in the NASH Patient Care process.
Louise Campbell hosts this week’s NASH Tsunami and talks about educating on liver outcomes. Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan provide their thoughts on education and social resources within the framework of developing a NAFLD pathway.
Louise Campbell hosts this week’s NASH Tsunami to talk about patient empowerment with Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan. The group explores measuring pathways and changing healthcare dynamics through digitization and technology.
Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this segment, the role of allied health professionals and patient empowerment is discussed in the context of developing a Sustainable Development Goal Framework for NAFLD.
Louise Campbell hosts this week’s NASH Tsunami and talks about the role of allied health professionals and patient empowerment in developing a NAFLD pathway. In this conversation, Jörn Schattenberg discusses a paper he co-authored that aims to guide multisectoral action on NAFLD through a societal approach.
Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this episode, the role of allied health professionals and patient empowerment is discussed in the context of a Sustainable Development Goal Framework for NAFLD.
This week, our conversation from the vault comes from Season 1 Episode 34 in November, 2020, the episode where our listeners first got to hear Jörn discussing his own work.
The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.
The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.
